PMID- 36915865
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230315
IS  - 2475-0379 (Electronic)
IS  - 2475-0379 (Linking)
VI  - 7
IP  - 2
DP  - 2023 Feb
TI  - Smoking and Activated Clotting Time during coronary angiography and angioplasty: 
      protocol for the ACT-Tobacco trial.
PG  - 100083
LID - 10.1016/j.rpth.2023.100083 [doi]
LID - 100083
AB  - BACKGROUND: During percutaneous transluminal coronary angioplasty (PTCA), 
      activated clotting time (ACT) measurements are recommended to attest a correct 
      anticoagulation level and, if needed, to administer further unfractionated 
      heparin (UFH) to obtain a therapeutic ACT value. Our clinical routine led us to 
      observe that smokers had lower ACT values after standardized UFH administration 
      during PTCA. Procoagulant status in smokers is well documented. OBJECTIVES: To 
      determine whether tobacco negatively affects UFH anticoagulation during PTCA when 
      evaluated by ACT. METHODS: The ACT-TOBACCO trial is a single-center, 
      noninterventional, prospective study. The primary end point is the comparison of 
      ACT values after standardized UFH administration between active smokers and 
      nonsmokers (active smoker group vs nonsmoker group) requiring coronary 
      angiography followed by PTCA. The main secondary end points include ACT 
      comparison after the first and second standardized UFH administration according 
      to the patient's smoking status (active, ex-, or nonsmoker) and the clinical 
      presentation of ischemic cardiomyopathy: stable (silent ischemia or stable 
      angina) or unstable (unstable angina or acute coronary syndrome without or with 
      ST-segment elevation). CONCLUSIONS: To the best of our knowledge, ACT values 
      during PTCA between smokers and nonsmokers have not previously been compared. As 
      current PTCA procedures increase in complexity and duration, the understanding of 
      procoagulant risk factors such as smoking and the need for reliable 
      anticoagulation monitoring becomes essential to balance hemorrhagic risk against 
      thrombotic risk.
CI  - (c) 2023 Published by Elsevier Inc. on behalf of International Society on 
      Thrombosis and Haemostasis.
FAU - Trimole, Regis
AU  - Trimole R
AD  - Department of Cardiology, University Hospital Nancy-Brabois, Vandoeuvre-les-Nancy, 
      France.
FAU - Manzi, Hugo
AU  - Manzi H
AD  - Department of Cardiology, Regional Hospital Metz-Thionville, Ars-Laquenexy, 
      France.
FAU - Hosseini, Kossar
AU  - Hosseini K
AD  - Clinical Research and Innovation Delegation, University Hospital Nancy-Brabois, 
      Vandoeuvre-les-Nancy, France.
FAU - Remen, Thomas
AU  - Remen T
AD  - Clinical Research and Innovation Delegation, University Hospital Nancy-Brabois, 
      Vandoeuvre-les-Nancy, France.
FAU - Toussaint-Hacquard, Marie
AU  - Toussaint-Hacquard M
AD  - Biological Hematology Laboratory, University Hospital Nancy-Brabois, 
      Vandoeuvre-les-Nancy, France.
FAU - Camenzind, Edoardo
AU  - Camenzind E
AD  - Department of Cardiology, University Hospital Nancy-Brabois, Vandoeuvre-les-Nancy, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20230214
PL  - United States
TA  - Res Pract Thromb Haemost
JT  - Research and practice in thrombosis and haemostasis
JID - 101703775
PMC - PMC10005900
OTO - NOTNLM
OT  - ACS, Acute Coronary Sryndrome
OT  - ACT, Activated Clotting Time
OT  - AT, Antithrombin
OT  - CathLab, Catheterization Laboratory
OT  - LMWH, Low Molecular-Weight Heparin
OT  - NOAC, Non-vitamin K Antagonist Oral Anticoagulants
OT  - POC, Point-of-Care
OT  - PT, Prothrombin Time
OT  - PTCA, Percutaneous Transluminal Coronary Angioplasty
OT  - SAS, Statistical Analysis System
OT  - UFH, Unfractionated Heparin
OT  - aPTT, Activated Partial Thromboplastin Time
OT  - activated coagulation time
OT  - coagulation
OT  - coronary angiography
OT  - heparin
OT  - i.a., Intra-Arterial
OT  - i.v., Intra-Venous
OT  - percutaneous transluminal coronary angioplasty
OT  - smoking
EDAT- 2023/03/15 06:00
MHDA- 2023/03/15 06:01
PMCR- 2023/02/14
CRDT- 2023/03/14 02:13
PHST- 2022/06/28 00:00 [received]
PHST- 2023/01/11 00:00 [revised]
PHST- 2023/01/25 00:00 [accepted]
PHST- 2023/03/14 02:13 [entrez]
PHST- 2023/03/15 06:00 [pubmed]
PHST- 2023/03/15 06:01 [medline]
PHST- 2023/02/14 00:00 [pmc-release]
AID - S2475-0379(23)00052-3 [pii]
AID - 100083 [pii]
AID - 10.1016/j.rpth.2023.100083 [doi]
PST - epublish
SO  - Res Pract Thromb Haemost. 2023 Feb 14;7(2):100083. doi: 
      10.1016/j.rpth.2023.100083. eCollection 2023 Feb.